First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study

OBJECTIVES: Brivaracetam (BRV) is the latest approved antiepileptic drug and acts as a synaptic vesicle protein 2A ligand. The aim of the present study was to evaluate the efficacy and tolerability of BRV in the clinical setting. DESIGN: Retrospective, observational multicentre study. SETTING: We re...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMJ Open
Main Authors: Menzler, Katja, Mross, Peter Michael, Rosenow, Felix, Schubert-Bast, Susanne, Willems, Laurent Maximilian, Zahnert, Felix, Immisch, Ilka, Fuest, Sven, von Podewils, Felix, Kunz, Rhina, Hirsch, Martin, Mueller, Tamara, Marquetand, Justus, Winter, Yaroslav, Langenbruch, Lisa, Cicanic, Michal, Beyenburg, Stefan, Strzelczyk, Adam, Knake, Susanne
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2019
Assuntos:
Neurology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6858140/
https://ncbi.nlm.nih.gov/pubmed/31690606
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2019-030746
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados